DTech Liquidating Years Dividend Increased

What does DTech Liquidating do? DTech Liquidating Inc, trading under the ticker DMTKQ with ISIN US24984K1051, is a U.S.-based company headquartered in San Diego. It operates within the Health Care sector, specifically in the Biotechnology industry. The company has 278 employees and completed its IPO on June 20, 2017. DTech Liquidating Inc is focused on the development and sale of products for the diagnosis and treatment of skin diseases. Its technology involves non-invasive genomics tests designed to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. The company utilizes a method that detects genomic markers associated with melanoma through non-invasive skin sample collection, aiming to identify higher-risk lesions at early stages to rule out melanoma. The DermTech Melanoma Test, also known as the DMT or Pigmented Lesion Assay (PLA), is marketed for the clinical assessment of pigmented skin lesions that may indicate melanoma. The company's products are intended to address unmet needs in the diagnostic process for pigmented skin lesions, commonly referred to as moles. DTech Liquidating Inc's operations are centered around providing innovative solutions for skin disease diagnosis and management, leveraging non-invasive genomic analysis techniques. DTech Liquidating is one of the most popular companies on Eulerpool.